Minimal change in structural, functional and inflammatory markers of lung disease in newborn screened infants with cystic fibrosis at one year
- PMID: 32044244
- DOI: 10.1016/j.jcf.2020.01.006
Minimal change in structural, functional and inflammatory markers of lung disease in newborn screened infants with cystic fibrosis at one year
Abstract
Background: With the widespread introduction of newborn screening for cystic fibrosis (CF), there has been considerable emphasis on the need to develop objective markers of lung health that can be used during infancy. We hypothesised that in a newborn screened (NBS) UK cohort, evidence of airway inflammation and infection at one year would be associated with adverse structural and functional outcomes at the same age.
Methods: Infants underwent lung function testing, chest CT scan and bronchoscopy with bronchoalveolar lavage (BAL) at 1 year of age when clinically well. Microbiology cultures were also available from routine cough swabs.
Results: 65 infants had lung function, CT and BAL. Mean (SD) lung clearance index and forced expiratory volume in 0.5 s z-scores were 0.9(1.2) and -0.6(1.1) respectively; median Brody II CF-CT air trapping score on chest CT =0 (interquartile range 0-1, maximum possible score 27). Infants isolating any significant pathogen by 1 yr of age had higher LCI z-score (mean difference 0.9; 95%CI:0.4-1.4; p = 0.001) and a trend towards higher air trapping scores on CT (p = 0.06). BAL neutrophil elastase was detectable in 23% (10/43) infants in whom BAL supernatant was available. This did not relate to air trapping score on CT.
Conclusions: In this UK NBS cohort at one year of age, lung and airway damage is much milder and associations between inflammation, abnormal physiology and structural changes were at best weak, contrary to our hypothesis and previously published reports. Continued follow-up will clarify longer term implications of these very mild structural, functional and inflammatory changes.
Keywords: Airway inflammation; Chest computed tomography; Cystic fibrosis; Infant lung function; Neutrophil elastase; Newborn screening.
Copyright © 2020. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest Dr. Brody reports grants and personal fees from Vertex Pharmaceuticals, outside the submitted work. Dr. Carr reports personal fees and other from Vertex Pharmaceuticals, other from Chiesi Pharmaceuticals, personal fees from Actavis Pharmaceuticals, other from Pharmaxis Pharmaceuticals, outside the submitted work. Dr Davies reports personal fees from Chiesi Pharmaceuticals, outside the submitted work. All other authors report no other potential competing interests.
Comment in
-
Minimal structural lung disease in early life represents significant pathology.J Cyst Fibros. 2021 Nov;20(6):e118-e120. doi: 10.1016/j.jcf.2020.12.010. Epub 2021 Jan 6. J Cyst Fibros. 2021. PMID: 33358120 No abstract available.
Similar articles
-
Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening.PLoS One. 2011;6(8):e23932. doi: 10.1371/journal.pone.0023932. Epub 2011 Aug 19. PLoS One. 2011. PMID: 21886842 Free PMC article.
-
Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.Am J Respir Crit Care Med. 2009 Jul 15;180(2):146-52. doi: 10.1164/rccm.200901-0069OC. Epub 2009 Apr 16. Am J Respir Crit Care Med. 2009. PMID: 19372250
-
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.JAMA. 2011 Jul 13;306(2):163-71. doi: 10.1001/jama.2011.954. JAMA. 2011. PMID: 21750293 Clinical Trial.
-
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.Cochrane Database Syst Rev. 2016 Jan 21;(1):CD009530. doi: 10.1002/14651858.CD009530.pub3. Cochrane Database Syst Rev. 2016. PMID: 26797965 Updated. Review.
-
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.Cochrane Database Syst Rev. 2013 Dec 23;(12):CD009530. doi: 10.1002/14651858.CD009530.pub2. Cochrane Database Syst Rev. 2013. PMID: 24363033 Updated. Review.
Cited by
-
Inflammation and Infection in Cystic Fibrosis: Update for the Clinician.Children (Basel). 2022 Dec 2;9(12):1898. doi: 10.3390/children9121898. Children (Basel). 2022. PMID: 36553341 Free PMC article. Review.
-
State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the "iMAging managEment of cySTic fibROsis" (MAESTRO) consortium.Eur Respir Rev. 2022 Mar 23;31(163):210173. doi: 10.1183/16000617.0173-2021. Print 2022 Mar 31. Eur Respir Rev. 2022. PMID: 35321929 Free PMC article. Review.
-
Foretelling Early Lung Disease Progression in Cystic Fibrosis: The Combined Benefits of Magnetic Resonance Imaging and Newborn Screening.Am J Respir Crit Care Med. 2021 Oct 15;204(8):880-881. doi: 10.1164/rccm.202107-1727ED. Am J Respir Crit Care Med. 2021. PMID: 34384036 Free PMC article. No abstract available.
-
Early Lung Disease Exhibits Bacteria-Dependent and -Independent Abnormalities in Cystic Fibrosis Pigs.Am J Respir Crit Care Med. 2021 Sep 15;204(6):692-702. doi: 10.1164/rccm.202102-0451OC. Am J Respir Crit Care Med. 2021. PMID: 34170795 Free PMC article.
-
Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing.Front Pediatr. 2021 Feb 25;9:635719. doi: 10.3389/fped.2021.635719. eCollection 2021. Front Pediatr. 2021. PMID: 33718306 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
